A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin

A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin

Abstract Background Type 2 diabetes (T2D) is a progressive disease that often requires a patient to use multiple antihyperglycemic agents to achieve glycemic control with disease progression. Omarigliptin is a once-weekly dipeptidyl peptidase-4 inhibitor. The purpose of this trial was to assess the...

Full description

Bibliographic Details
Main Authors: Seung-Hwan Lee, Ira Gantz, Elizabeth Round, Melanie Latham, Edward A. O’Neill, Paulette Ceesay, Shailaja Suryawanshi, Keith D. Kaufman, Samuel S. Engel, Eseng Lai
Format: Article
Language:English
Published: BMC 2017-11-01
Series:BMC Endocrine Disorders
Subjects:
MK-3102
Incretin therapy
Oral antihyperglycemic agent
Online Access:http://link.springer.com/article/10.1186/s12902-017-0219-x

Similar Items

Similar Items